Post-marketing requirements and commitments

At Roche and Genentech, patient safety is a priority. These post-authorisation safety studies demonstrate our commitment.

Please click the icons to learn more

Abbreviations

LMP, last menstrual period; OCR, ocrelizumab; pwMS, people with MS; SAE, serious adverse event; US, United States.

M-XX-00019322 (Date of preparation: December 2024)